ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	74.29	150.39	163.37	37.28
Short-Term Investments	144.57	-	-	-
Cash & Short-Term Investments	218.86	150.39	163.37	37.28
Cash Growth	45.53%	-7.95%	338.23%	-
Other Receivables	0.5	0.76	0.5	0.25
Receivables	0.5	0.76	0.5	0.25
Prepaid Expenses	0.41	0.37	0.33	0.03
Other Current Assets	7.21	8.45	18.42	5.39
Total Current Assets	226.98	159.97	182.62	42.95
Property, Plant & Equipment	0.15	0.29	0.14	-
Long-Term Investments	47.68	-	-	-
Long-Term Deferred Charges	-	2.73	-	-
Other Long-Term Assets	0.13	0.11	0.07	0.09
Total Assets	274.94	163.1	182.83	43.04
Accounts Payable	3.78	4.53	3.09	0.29
Accrued Expenses	13.33	6.95	5.14	1.53
Current Portion of Leases	0.16	0.14	0.13	-
Total Current Liabilities	17.27	11.62	8.36	1.82
Long-Term Leases	0.01	0.18	0.01	-
Total Liabilities	17.29	11.8	8.37	1.82
Common Stock	0	-	-	-
Additional Paid-In Capital	496.2	4.65	3.4	2.96
Retained Earnings	-238.33	-157.85	-88.51	-51.61
Comprehensive Income & Other	-0.21	-	-	-0
Total Common Equity	257.65	-153.19	-85.11	-48.64
Shareholders' Equity	257.65	151.3	174.46	41.22
Total Liabilities & Equity	274.94	163.1	182.83	43.04
Total Debt	0.18	0.32	0.14	-
Net Cash (Debt)	218.69	150.07	163.23	37.28
Net Cash Growth	45.72%	-8.06%	337.86%	-
Net Cash Per Share	6.95	70.10	127.82	52.42
Filing Date Shares Outstanding	34.02	33.49	31.96	0.71
Total Common Shares Outstanding	33.71	2.75	2.6	0.71
Working Capital	209.71	148.34	174.26	41.13
Book Value Per Share	7.64	-55.80	-32.76	-68.40
Tangible Book Value	257.65	-153.19	-85.11	-48.64
Tangible Book Value Per Share	7.64	-55.80	-32.76	-68.40

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q